Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| CA CARMCarisma Therapeutics | $0.00-47.8% | $50,214 | 5 assetsStage unavailable | No dated catalyst | |
| CA CASICASI Pharmaceuticals Inc | $0.21+0.0% | $4.3M | 6 assetsStage unavailable | No dated catalyst | |
| CA CATXPerspective Therapeutics | $3.30+2.8% | $376.7M |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
4 assetsPhase 1/2 |
[212Pb]VMT-α-NETPhase 1/2 · Data readout |
| CB CBAYCymaBay Therapeutics | $32.48+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| CB CBIOCrescent Biopharma Inc | $17.15+5.7% | $637.0M | 5 assetsPhase 1/2 | CR-003 (Topoisomerase Inhibitor ADC)Phase 1/2 · Data readout |
| CC CCCCC4 Therapuetics | $4.00-0.7% | $492.1M | 4 assetsPhase 1 | Cemsidomide (CFT7455) +/- dexamethasonePhase 1 · Data readout |
| CD CDTXCidara Therapeutics | $221.38+0.0% | $6.96B | 3 assetsStage unavailable | No dated catalyst |
| CE CELCCelcuity | $93.53+3.3% | $4.58B | 6 assetsApproved | Gedatolisib + darolutamide (Nubeqa®)Phase 1b · Data readout |
| CE CELUCelularity | $0.80-2.0% | $23.2M | 1 assetsStage unavailable | No dated catalyst |
| CF CFRXContraFect Corporation | $0.05-28.0% | — | 3 assetsStage unavailable | No dated catalyst |
| CG CGEMCullinan Management | $21.68+1.4% | $1.33B | 14 assetsPDUFA | ZipalertinibPhase 3 · Data readout |
| CG CGENCompugen | $2.62-1.3% | $247.7M | 11 assetsPhase 2 | No dated catalyst |
| CG CGONCG Oncology | $79.81+2.8% | $7.07B | 4 assetsPhase 3 | CretostimogenePhase 3 · Data readout |
| CG CGTXCognition Therapeutics | $1.00+4.1% | $94.7M | 4 assetsPhase 2 | Zervimesine (CT1812) Phase 2 · Data readout |
| CH CHRSCoherus BioSciences Inc. | $1.42+7.6% | $219.4M | 17 assetsPhase 2 | Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1)Phase 1/2 · Data readout |
| CI CINGCingulate Inc | $5.55+4.1% | $80.7M | 3 assetsStage unavailable | No dated catalyst |
| CK CKPTCheckpoint Therapeutics | $4.26+0.0% | $370.7M | 3 assetsStage unavailable | No dated catalyst |
| CL CLDXCelldex Therapeutics, Inc. | $40.38+1.1% | $3.17B | 9 assetsPhase 3 | Barzolvolimab (CDX-0159) (KIT receptor) Phase 3 · Data readout |
| CL CLLSCellectis | $3.41-1.9% | $342.9M | 9 assetsPhase 2 | UCART20x22Phase 1 · Data readout |
| CL CLNNClene Inc | $4.32-1.1% | $55.5M | 4 assetsStage unavailable | No dated catalyst |
| CL CLRBCellectar Biosciences | $2.59+0.0% | $24.5M | 6 assetsPhase 1b | No dated catalyst |
| CL CLSDClearside Biomedical | $0.41+0.0% | $2.1M | 5 assetsStage unavailable | No dated catalyst |
| CL CLYMClimb Bio | $17.28+1.5% | $992.5M | 10 assetsPhase 2 | CLYM116 (Anti-APRIL Antibody)Phase 1 · Data readout |
| CM CMMBChemomab Therapeutics | $2.16+4.3% | $15.8M | 2 assetsStage unavailable | No dated catalyst |
| CM CMPICheckmate Pharmaceuticals Inc. | $10.50+0.0% | — | 4 assetsStage unavailable | No dated catalyst |
| CM CMPSCompass Pathways | $13.33-3.5% | $1.85B | 3 assetsStage unavailable | No dated catalyst |
| CM CMPXCompass Therapeutics | $2.40+1.7% | $432.2M | 6 assetsPhase 2/3 | Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody)Phase 2/3 · Data readout |
| CM CMRXChimerix Inc. | $8.54+0.0% | $801.1M | 4 assetsStage unavailable | No dated catalyst |
| CN CNSYCerenome, Inc. | $3.07+2.3% | $23.3M | 5 assetsPhase 2 | REYOBIQ (Rhenium Re186 Obisbemeda)Phase 2 · Data readout |
| CN CNTACentessa Pharmaceuticals | $40.50+0.0% | $6.27B | 7 assetsStage unavailable | No dated catalyst |
| CN CNTBConnect Biopharma | $2.36+3.5% | $148.6M | 10 assetsPhase 2 | Rademikibart /CBP-201 Phase 2 · Data readout |
| CN CNTXContext Therapeutics | $0.50-3.8% | $45.9M | 6 assetsStage unavailable | No dated catalyst |
| CO COAGHemab Therapeutics Holdings, Inc. | $49.16+2.0% | $2.30B | 4 assetsPhase 2 | HMB-002Phase 1/2 · Data readout |
| CO COCPCocrystal Pharma | $1.15-1.7% | $22.2M | 5 assetsStage unavailable | No dated catalyst |
| CO COEPCoeptis Therapeutics | $3.35+15.9% | $102.1M | 1 assetsStage unavailable | No dated catalyst |
| CO COGTCogent Biosciences Inc | $36.73+4.0% | $6.37B | 6 assetsPDUFA | Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + SunitinibPDUFA · Approval decision |
| CO COLLCollegium Pharmaceutical | $27.11-1.6% | $840.4M | 7 assetsStage unavailable | No dated catalyst |
| CO CORTCorcept Therapeutics | $122.25+1.0% | $13.22B | 16 assetsApproved | RelacorilantPDUFA · Approval decision |
| CO COYACoya Therapeutics | $4.87+0.2% | $114.2M | 3 assetsPhase 2 | COYA 301 (Low Dose IL-2)Phase 2 · Data readout |
| CP CPIXCumberland Pharmaceuticals Inc. | $7.65+2.0% | $114.6M | 5 assetsStage unavailable | No dated catalyst |